AR044949A1 - MUTANTS OF IFNAR2, ITS PRODUCTION AND USE - Google Patents

MUTANTS OF IFNAR2, ITS PRODUCTION AND USE

Info

Publication number
AR044949A1
AR044949A1 ARP040102282A AR044949A1 AR 044949 A1 AR044949 A1 AR 044949A1 AR P040102282 A ARP040102282 A AR P040102282A AR 044949 A1 AR044949 A1 AR 044949A1
Authority
AR
Argentina
Prior art keywords
ifnar2
polypeptide
ifn
medicament
beta
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Yeda Resarch And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Resarch And Dev Co Ltd filed Critical Yeda Resarch And Dev Co Ltd
Priority to ARP040102282 priority Critical patent/AR044949A1/en
Publication of AR044949A1 publication Critical patent/AR044949A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un polipéptido mutante del IFNAR2 (MIFNAR2) mutado en residuos de aminoácidos histidina 78 y asparagina 100, que posee mayor afinidad para el interferón-beta (INF-beta) que el polipéptido de tipo silvestre, o un análogo, derivado funcional, proteína de fusión o sal del mismo. Reivindicación 16: Un ADN que codifica un polipéptido de acuerdo con cualquiera de las reivindicaciones 1-14. Reivindicación 25: El uso del mutante el IFNAR2 de acuerdo con cualquiera de las reivindicaciones 1 a 15 en la fabricación de un medicamento. Reivindicación 26: El uso de acuerdo con la reivindicación 25, donde el medicamento también comprende el IFN. Reivindicación 29: El uso de acuerdo con cualquiera de las reivindicaciones 25 a 28, para modular los efectos del IFN.An IFNAR2 mutant polypeptide (MIFNAR2) mutated in amino acid residues histidine 78 and asparagine 100, which has a greater affinity for interferon-beta (INF-beta) than the wild-type polypeptide, or an analogue, functional derivative, fusion protein or get out of it. Claim 16: A DNA encoding a polypeptide according to any one of claims 1-14. Claim 25: Use of the IFNAR2 mutant according to any one of claims 1 to 15 in the manufacture of a medicament. Claim 26: The use according to claim 25, wherein the medicament also comprises the IFN. Claim 29: Use according to any of claims 25 to 28, to modulate the effects of IFN.

ARP040102282 2004-06-29 2004-06-29 MUTANTS OF IFNAR2, ITS PRODUCTION AND USE AR044949A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP040102282 AR044949A1 (en) 2004-06-29 2004-06-29 MUTANTS OF IFNAR2, ITS PRODUCTION AND USE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040102282 AR044949A1 (en) 2004-06-29 2004-06-29 MUTANTS OF IFNAR2, ITS PRODUCTION AND USE

Publications (1)

Publication Number Publication Date
AR044949A1 true AR044949A1 (en) 2005-10-12

Family

ID=42778309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102282 AR044949A1 (en) 2004-06-29 2004-06-29 MUTANTS OF IFNAR2, ITS PRODUCTION AND USE

Country Status (1)

Country Link
AR (1) AR044949A1 (en)

Similar Documents

Publication Publication Date Title
ECSP024346A (en) PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR METHODS OF PHARMACOLOGICAL USE
ATE466085T1 (en) PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
LU91680I2 (en) "rilonacept and its pharmaceutically acceptable derivatives (ARCALYSR)"
DE602006020123D1 (en) GLUCAGON LIKE PEPTIDE-2 (GLP-2) ANALOG
BRPI0512286A (en) angiogenesis inhibiting chimeric proteins and the use
CR20110245A (en) MUTANTS FGF21 AND USE OF THE SAME.
ATE544461T1 (en) RECONSTITUTED SURFACTANTS WITH IMPROVED PROPERTIES
ES8608043A1 (en) Pharmaceutical and veterinary preparations of cystein-125-depleted muteins of Interleukin-2 and their production.
DK1132403T3 (en) TGF G Beta1 Inhibitor Peptides
DE60125381D1 (en) COMPOSITIONS AND METHODS FOR ANALOGUE OF G-CSF
ATE388165T1 (en) HUMAN CNP GENE AND PRECUSSION PROTEIN
ATE490323T1 (en) ADIPONECTIN RECEPTOR AND GENE CODING IT
BRPI0207933B8 (en) Mutant interleukin-18 polypeptide and pharmaceutical composition
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
BR0312521A (en) Methods for the separation and purification of fibrinogen and at least one other protein and for the co-purification of fibrinogen and factor xiii, use of immobilized metal ion affinity chromatography, fibrinogen, pharmaceutical kit, and pharmaceutical formulations and freeze-dried fibrinogen
ATE417618T1 (en) HIGH EXPRESSION LEVEL FACTOR VIII POLYPEPTIDES CODING NUCLEIC ACID AND AMINO ACID SEQUENCES AND METHODS OF USE
MX9300741A (en) PARTICLES OF HARD MATERIAL, BASED ON OXIDES AND PROCEDURE FOR ITS OBTAINING.
ATE520776T1 (en) RECOMBINANT HERPES VIRUS AND USE THEREOF
DE69435177D1 (en) Chemoattraction triggering factor from lymphocytes and its use
DK1373502T3 (en) Dopaminergic neuronal survival promoting factors and their causes
ES2169384T3 (en) CHROMATOGRAPHIC PROCEDURE FOR OBTAINING HIGHLY PURIFIED CYCLOSPORIN AND ANALOG CYCLOSPORINS.
AR044949A1 (en) MUTANTS OF IFNAR2, ITS PRODUCTION AND USE
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
RS52448B (en) Antitumoral pharmaceutical composition containing polypeptide fragments of serralyysins
DK1478659T3 (en) Biologically active peptides

Legal Events

Date Code Title Description
FC Refusal